VASCULAR BIOGENICS IS-,01 WKN: A119YE ISIN: IL0011327454 Forum: Aktien Thema: Hauptdiskussion

👀

Geht hier was

Wurde auch Zeit. Mit kleinem Plus raus.

🎉🎊

Merger Is Expected To Close In Q2 Of 2023

🎈

VBLT - VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement ‼️

👀

Bin mal zu 0,195 rein. Mal schauen. Zock auf NC ....

Bin am überlegen hier rein zu gehen …

Da geht noch was ...

Niemand investiert?

Was meint der ihr? Überlege zu verkaufen? Laut Chart gerade eine schöner Stand? 23 Prozent plus bei mir.

https://clinicaltrials.gov/ct2/results?cond=&term=vascular+Biogenics&cntry=&state=&city=&dist= 381 gelistete Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P20-K4D3VG-22927

The VBLT Opportunity Three novel platform technologies, with innovative mechanisms of action and strong IP • Lead candidate VB-111 in a Phase 3 potential-registration study for ovarian cancer • Final Phase 2 results in ovarian cancer were presented at ASCO 2019 • Phase 3 Interim analysis data expected 1Q 2020 • Two new Phase 2 investigator/NCI-sponsored studies expected to start soon • Potential across multiple solid tumors • In house commercial-scale gene therapy GMP manufacturing facility (20,000 sq.ft.) • Strategic deal on VB-201 for veterinary use, with potential of €50M payments to VBL • Two new antibody programs, in inflammation & oncology, advanced towards IND filing • Cash position secured for about 2 years, clear capital focus, no debt

Katalysatoren in Q1: - Launch of NCI-sponsored study of VB-111 in combination with checkpoint inhibitor in colon cancer - Launch of investigator-sponsored randomized controlled study of VB-111 in rGBM - OVAL study Interim analysis Katalysator in H1 - Pre IND submission MOSPD2 Inflammation program Katalysator Q4 - OVAL study second interim data Katalysator EOY - Preliminary Readout of VB-111 trial in colon cancer